NEW YORK, April 1 - Ingenuity Systems said today that it is partnering with non-profit foundations ABC2 (Accelerate Brain Cancer Cure) and CaP Cure (Association for the Cure of Cancer of the Prostate) to test existing chemotherapeutic agents against gene defects associated with prostate and brain cancer pathways.
Researchers from Cedars-Sinai Medical Center, University of Michigan, University of California, San Francisco, and University of California, Los Angeles, will participate in the program. They will use Ingenuity's Pathways Knowledge Base, a curated model of biological pathways, as well as the company's pathways software, which computationally predicts disease pathways from genomic data.
The project aims to better understand which genetic pathways are active in brain and prostate cancer, and which approved or late-stage experimental drugs may disrupt the pathways.
"Through a better understanding of how cancer pathways interact, we expect to be able to take existing drugs and in a fraction of the time compared to novel compounds, be able to demonstrate new ways to enhance patient care," said David Agus of Cedars-Sinai Medical Center.